Scinai reports 167% revenue growth in first nine months of 2026
Scinai Immunotherapeutics Ltd. reported revenue of $2.8 million for the nine months ended September 30 2026, up 167% from $1.05 million in the same period last year. The company cited expansion of its CDMO business, including the Yavne operations acquired on February 16 2026, as the primary driver of the increase.
Primary source
Company press release (PR Newswire), November 5, 2026
Scinai Reports Significant Revenue Growth in First Nine Months of 2026 as CDMO Business Expands
Read the source: Scinai Reports Significant Revenue Growth in First Nine Months of 2026 as CDMO Business Expands prnewswire.com
Machine-summarized from the source above; not independently reported. How we use automation